What most clinical summaries get wrong about psilocybin and PTSD.

THE DISPATCH

Fewer than 30% of veterans with treatment-resistant PTSD respond meaningfully to first-line interventions. SSRIs and cognitive processing therapy remain the standard of care, and the combined data on their efficacy in the most severe cases is not encouraging.¹ The compound that is beginning to move that number works in a way that most clinical summaries get wrong. And understanding the mechanism is what determines whether you evaluate this medicine, or this field, correctly.

We are in the early stages of what the clinical record will eventually describe as a structural shift in how trauma is treated.

In this issue:

→ The neuroplasticity window: what psilocybin actually does, and why the compound is not the treatment

→ One veteran's account of what that window felt like, and what the follow-up data showed

→ The VA's commitment to psychedelic research and what it signals for where access is heading

---

THE SCIENCE

Psilocybin is a serotonin 2A receptor agonist (5-HT2A). When administered in a controlled clinical setting, it produces a well-documented cascade of neural effects: significant suppression of the default mode network, the brain's self-referential processing hub responsible for habitual thought patterns and the rumination loops that define chronic PTSD, alongside a sharp increase in global neural connectivity between regions that do not ordinarily communicate.² The subjective experience this produces has been extensively documented. The underlying mechanism is what matters clinically.

What the 5-HT2A agonism initiates is a temporary state of heightened neuroplasticity. The brain's capacity to form new synaptic connections is measurably elevated, driven in part by increased expression of brain-derived neurotrophic factor (BDNF), a protein directly implicated in neural growth and adaptation.³ This window does not last indefinitely. Its acute phase is measured in hours. The elevated plasticity in the days that follow is the extended opportunity.

What the clinical summaries describe as psilocybin "treating PTSD" is not quite accurate. The distinction matters for anyone evaluating this medicine, whether as a patient, a clinician, or an investor.

The compound does not directly resolve trauma. What it does is create a temporary neurological environment in which therapeutic work becomes possible in ways it was not before. The rigid, repetitive fear-response pathways of PTSD, carved deep by avoidance and repetition, are temporarily disrupted. The brain's habitual routing is interrupted. In that window, the therapeutic framework applied determines where the new pathways form.

This is why two people can receive the same compound, at the same dose, in the same facility, and have substantially different clinical outcomes. The variable is not the molecule. The variable is what happens inside the window.

For a patient with treatment-resistant PTSD, this reframe carries practical weight. Psilocybin-assisted therapy is not passive. The compound opens a door. The preparation before, the guided processing during, and the structured integration after are what the door is for. Programs that treat the administration as the primary event, rather than the window it creates, are not using the mechanism correctly.

Think of the trauma-conditioned brain like a road network where one route, the fear response, has been travelled so many times it has become a six-lane freeway, while every other path has overgrown. Psilocybin doesn't simply widen those other paths. Temporarily, it tears up the pavement on the freeway. The therapeutic work determines where new roads are built. Without the work, the old route simply re-hardens.

For a clinician advising patients, this means preparation and integration protocols carry clinical weight equal to the pharmacology. The research consistently supports this: trials with structured therapeutic frameworks surrounding the compound show meaningfully stronger outcomes than those treating it as a standalone intervention.⁴

For an investor evaluating a program or trial, the most important question is not "what dose?" but "what happens during and after the window?" That is where differentiated clinical value is built, and where most early-stage programs diverge.

The neuroplasticity window is temporary. The pathways formed within it are not. This is the mechanism. It is also why the therapeutic framework, who delivers it, how they prepare the patient, and what follows, is the most undervalued variable in evaluating any psilocybin program.

Psilocybin doesn't treat PTSD. It creates a neurological window where treatment can finally work. That distinction changes everything about how to evaluate this medicine.

The real-world data from structured veteran programs offers the clearest early signal of what that window produces when the therapeutic framework is right.

---

THE STORY

A combat veteran with a documented history of traumatic brain injury and treatment-resistant PTSD. Prior interventions had not produced lasting relief. He enrolled in a structured psilocybin retreat program involving preparation, guided sessions, and post-session integration.

At follow-up, his clinician-administered PTSD symptom scores had dropped meaningfully, alongside normalisation of spontaneous brain activity on EEG — an objective neurological marker, not a self-report. He described the shift as "finally being able to look at the thing without becoming the thing."⁵

That is not clinical language. The EEG data is.

His outcome reflects findings from a 2024 peer-reviewed study documenting improved mental health outcomes and normalised EEG activity in veterans with TBI history following participation in a structured psilocybin retreat.⁵ The mechanism described above is the current best explanation for why those outcomes held.

---

ON OUR RADAR

① The VA Is Funding Psychedelic Research. There's a Catch. The VA approved $50-100M for psychedelic-assisted PTSD research. Veterans who disclose psilocybin therapy still risk losing their benefits. The institution is in. The access gap remains. Watch for trial announcements over the next 12 months.⁶

② One Dose. 12 Weeks of Improvement. Compass Just Published the PTSD Data. A single 25mg dose of synthetic psilocybin produced durable PTSD symptom improvement out to 12 weeks in Compass Pathways' Phase 2. No serious adverse events. If Phase 3 holds, this would be the first pharmacological advance in PTSD treatment in two decades.⁷

③ Johns Hopkins Just Launched Psilocybin for Stroke. The Mechanism Is the Same. A Phase 1 trial is now investigating psilocybin for motor recovery in chronic stroke survivors at Johns Hopkins, led by Dr. Gül Dölen. Same neuroplasticity window, entirely different patient population. Operating under an exclusive license with Rose Hill Life Sciences.⁸

---

YOU ASKED

Q: "How is psilocybin different from an antidepressant, aren't they both just drugs that affect serotonin?"

The mechanism is different in kind, not degree. An SSRI modulates serotonin availability continuously. Taken daily, it maintains a modified neurological baseline. It manages the system. Psilocybin binds acutely to the 5-HT2A receptor, producing a temporary state of elevated neuroplasticity: a window, not a sustained shift.² The brain is not being managed. It is being given a targeted opportunity to reorganise. SSRIs are long-term maintenance; psilocybin-assisted therapy is a discrete intervention that creates conditions for structural change. They are not competing approaches. But they are not the same category of medicine. Conflating them leads to setting the wrong expectations about what the therapy actually requires of the patient. That distinction, between managing a system and creating a window for it to reorganise, is precisely where Rose Hill's program design focuses. The integration framework is not peripheral to the treatment. It is the treatment.

---

This week's takeaway: before evaluating any psilocybin program, whether as a patient, a clinician, or an investor, ask one question: what is the integration protocol? The mechanism tells you why that question matters more than any other. The compound opens the window. The protocol determines what is built inside it.

A question worth sitting with: what would it mean for mental health treatment if the compound was never the active ingredient, and the window was?

Read the published Compass Pathways Phase 2 PTSD trial results: Compass Pathways IR

Know a veteran still cycling through treatments that aren't working? Forward them this. Not as a recommendation. As information they deserve to have.

— Domenic Suppa

Co-founder, Rose Hill Life Sciences

Advancing the development of novel psychedelic-based therapeutics

---

FOOTNOTES

¹ Steenkamp, M.M., et al. "Psychotherapy for Military-Related PTSD: A Review of Randomized Clinical Trials." JAMA, 314(5), 489-500, 2015. https://doi.org/10.1001/jama.2015.8370

² Carhart-Harris, R.L., et al. "Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin." Proceedings of the National Academy of Sciences, 109(6), 2138-2143, 2012. https://doi.org/10.1073/pnas.1119598109

³ Ly, C., et al. "Psychedelics Promote Structural and Functional Neural Plasticity." Cell Reports, 23(11), 3170-3182, 2018. https://doi.org/10.1016/j.celrep.2018.05.022

⁴ Carhart-Harris, R., et al. "Trial of Psilocybin versus Escitalopram for Depression." New England Journal of Medicine, 384, 1402-1411, 2021. https://doi.org/10.1056/NEJMoa2032994

⁵ "Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat." PubMed, 2024. https://pubmed.ncbi.nlm.nih.gov/40842948/

⁶ Department of Veterans Affairs psychedelic research funding, 2024-2025.

⁷ Compass Pathways. "Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder." GlobeNewswire, 2025.

⁸ Rose Hill Life Sciences. "Rose Hill Life Sciences Executes Exclusive License Agreement with Johns Hopkins University for Restoration of Motor Function Post-Neurological Injury Using Psychedelics." GlobeNewswire, June 2025.

---

The Rose Hill Review